U.S. markets closed

Reflect Scientific, Inc. (RSCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.7000+0.0185 (+2.71%)
At close: 3:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6815
Open0.7000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.6400 - 0.7390
52 Week Range0.0300 - 3.3000
Volume848,652
Avg. Volume1,822,747
Market Cap59.317M
Beta (5Y Monthly)2.65
PE Ratio (TTM)N/A
EPS (TTM)-0.0020
Earnings DateNov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reflect Scientific Inc Receives Sales Contract for Cryometrix Freezers
    GlobeNewswire

    Reflect Scientific Inc Receives Sales Contract for Cryometrix Freezers

    OREM, Utah, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries, announces a $416K sales contract for Cryometrix B-90 blast freezers from a prominent pharmaceutical company. A significant $416K order has been placed for Cryometrix B-90 blast freezers destined to ship to the US and the British Isles. The Cryometrix B-90 blast freezer is an ultra-cold refrigeration product that can rapidly cool the payload bay from +20C (68F) to -80C (-130F) in 7 minutes. The freezer technology covered under several patents uses a closed liquid nitrogen system keeping the liquid nitrogen from contact with the payload and personnel. The B-90 freezer is used in the process of creating and storing the newest biopharmaceuticals and mRNA vaccines.Mr. Kim Boyce, CEO of Reflect Scientific Inc, remarked, “The B-90 is a great fit for pharmaceutical companies engaged in vaccine and biopharmaceutical manufacturing. It is essentially the only blast freezer on the market that can achieve a rapid cooling rate while maintaining excellent temperature uniformity and, in addition, able to maintain a precise storage temperature. It’s a dream come true for them.”About Reflect Scientific, Inc. Reflect Scientific, Inc., based in Orem, Utah, develops and markets innovative, proprietary technologies in cryogenic cooling for the biotechnology, pharmaceutical, medical, and transportation markets. Among Reflect Scientific’s products are low-temperature freezers and refrigerated systems for laboratory, transportation, and computer server room uses. Visit www.reflectscientific.com for more information. See us on Twitter @ReflectSci and LinkedIn www.linkedin.com/company/reflect-scientific.Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of the disclosures contained in the filings of the Company that are contained in the OTC Markets Group, LLC under the trading symbol “RSCF” and related prior filings by the Company that are referenced therein and contained in the EDGAR Archives of the Securities and Exchange Commission under the heading “Disclosure,” including those identified in such filings as “forward-looking statements.” CONTACT: Contact Thomas Tait 801-607-1039 investor_relations@reflectscientific.com

  • In Addition to Addressing COVID Vaccine Shipping and Storage Requirements, Reflect Scientific’s Proprietary Liquid Nitrogen-based Freezers are Continuing to Support Growing Cell and Gene Therapy Market Requirements for Ultra-Low Temperature Processing and Storage
    GlobeNewswire

    In Addition to Addressing COVID Vaccine Shipping and Storage Requirements, Reflect Scientific’s Proprietary Liquid Nitrogen-based Freezers are Continuing to Support Growing Cell and Gene Therapy Market Requirements for Ultra-Low Temperature Processing and Storage

    OREM, Utah, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), is a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries. Reflect Scientific continues to penetrate the Cell and Gene Therapy (CGT) market with its unique Ultra-Low temperature processing and storage products.The CGT market is expected to reach approximately 13 billion dollars by 2024 from 3.8 billion in 2019 at a CAGR of 27.8 %. Market growth is driven by the emergence of new cell-based technologies that are being transitioned into new therapeutics supported by new diagnostic technologies to address cancer and other diseases at the cell level. North America accounts for the largest share of the CGT market. Companies currently participating in the Cell and Gene Therapy market include Gilead Sciences / Kite, Bristol-Myers Squibb / Juno, Novartis AG, GSK, Pfizer, Johnson & Johnson and Bluebird Bio. It is interesting to note that more than 900 clinical trials are currently underway supporting new compound development for the CGT market.Reliable temperature management of related products is critically important and generally ranges from a level of -20C to -150C. Meeting these requirements using an upright ultra-low temperature freezer presents a very difficult challenge for mechanical based systems.Our commercially proven Cryometrix T-90 and T-150 systems address these concerns by providing a market-based solution. These systems are designed to provide flexible temperature set point control, operational reliability and predictability across a range of temperature set points down to as low as -150C. Blast freezing can also be an important manufacturing process step, which involves the rapid cooling of process fluids. Our Cryometrix B-90 has already shown significant advantages over mechanical system limitations due to its greater thermodynamic efficiency, which has resulted in major reductions and predictability of processing times. Cryometrix technologies address perceived constraints in the CGT market and turn them into Manageable Limitations.About Reflect Scientific, Inc. Reflect Scientific, Inc., based in Orem, Utah, develops and markets innovative, proprietary technologies in cryogenic cooling for the biotechnology, pharmaceutical, medical, and transportation markets. Among Reflect Scientific’s products are low-temperature freezers and refrigerated systems for laboratory, transportation, and computer server room uses. Visit www.reflectscientific.com for more information. See us on Twitter @ReflectSci and LinkedIn www.linkedin.com/company/reflect-scientific.Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of the disclosures contained in the filings of the Company that are contained in the OTC Markets Group, LLC under the trading symbol “RSCF” and related prior filings by the Company that are referenced therein and contained in the EDGAR Archives of the Securities and Exchange Commission under the heading “Disclosure,” including those identified in such filings as “forward-looking statements.”ContactThomas Tait801-607-1039investor_relations@reflectscientific.com

  • Reflect Scientific Inc. Adds Another Low Temperature Refrigeration Patent Solution to its Growing Intellectual Property Portfolio, and Business Update
    GlobeNewswire

    Reflect Scientific Inc. Adds Another Low Temperature Refrigeration Patent Solution to its Growing Intellectual Property Portfolio, and Business Update

    OREM, Utah, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries, announced that an additional patent has been granted by United States Patent Office for an ultra-low temperature (-160C) chest freezer based on the proven Cryometrix liquid nitrogen cooling technology. Ultra-low temperature mechanical freezers face unique issues. Lack of temperature uniformity throughout the storage volume can be a problem for both upright and chest freezers. Opening and closing the door creates a large influx of warm air causing an extended temperature recovery time. Reflect Scientific has already addressed this concern for upright freezers with its unique liquid nitrogen based Cryometrix system. A recently issued Reflect Scientific patent now addresses these concerns with a superior chest freezer design. The Cryometrix chest freezer temperature stability and resistance to warm air infiltration during opening provides a very consistent, controlled low temperature environment that can be relied upon for safely storing high value products such as CAR-T therapeutics. This patented technology provides the next level of temperature uniformity and control. The cold chain management of COVID vaccines continues to present challenges in storage and distribution; and we believe our patented freezer technology could have a favorable and positive impact on the current pandemic and would be a valuable asset for the distribution and storage of the current COVID-19 vaccines that require storage at extremely cold temperatures.  On our sales front, we have several freezer systems scheduled for shipment this year, with a number of other orders anticipated in the first quarter of 2021 from multiple worldwide pharmaceutical companies; we are pleased with the level of activity we are seeing, and remain optimistic that the Company may realize positive earnings per share for 2020. The Company is presently debt free.In the area of cold chain management, we are continuing discussions with a major supplier of air transport containers regarding the integration of our liquid nitrogen systems to enable cooling and temperature control of sensitive payloads.We are still awaiting response from Operation Warp Speed, a FEMA contractor, and other organizations, from who we have received inquiries for our Cryometrix S-90 cryogenic shipping and storage system. These systems can also serve as a cold (e.g. -80C) storage unit once at destination. We do have a large-scale manufacturing capability should these inquires firm up. In terms of the competitive advantages of our products, we believe the Cryometrix liquid nitrogen freezers offer the following principal benefits versus mechanically driven ULT's or the utilization of dry ice. They can: (i) accommodate a wide range of temperature storage conditions (i.e. anywhere from room temperature to as low as -90C); (ii) have a very rapid temperature recovery from door openings, making it safer, for example, in maintaining COVID vaccines at the desired critical temperature; and (iii) the Cryometrix liquid nitrogen system has a very high operational reliability, keeping potential waste of valuable payloads to essentially zero compared to mechanically driven freezers that can be susceptible to failure.We do not require dry ice, which has temperature limitations. Dry ice is limited to -78.5C (the current Pfizer vaccine has been reported to require -80C); and dry ice can also present challenges with respect to handling. On the other hand, liquid nitrogen in the Cryometrix system is in a contained environment.Cryometrix freezers typically show higher storage capacity per footprint compared to mechanical freezers, and they have excellent temperature uniformity throughout the payload space with essentially no build-up of ice on payload. The newly granted patent for a “chest” freezer will be a welcome and important addition to our Cryometrix freezers.Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of the disclosures contained in the filings of the Company that are contained in the OTC Markets Group, LLC under the trading symbol “RSCF” and related prior filings by the Company that are referenced therein and contained in the EDGAR Archives of the Securities and Exchange Commission under the heading “Disclosure,” including those identified in such filings as “forward-looking statements.”Contact Thomas Tait 801-607-1039 info@reflectscientific.com